Achieve Life Sciences, Inc.
ACHV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $23 | $16 | $30 | $24 |
| G&A Expenses | $16 | $11 | $11 | $9 |
| SG&A Expenses | $16 | $11 | $11 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $39 | $27 | $41 | $33 |
| Operating Income | -$39 | -$27 | -$41 | -$33 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$3 | -$2 | -$0 |
| Pre-Tax Income | -$40 | -$30 | -$42 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40 | -$30 | -$42 | -$33 |
| % Margin | – | – | – | – |
| EPS | -1.24 | -1.5 | -3.95 | -4.05 |
| % Growth | 17.3% | 62% | 2.5% | – |
| EPS Diluted | -1.24 | -1.5 | -3.95 | -4.05 |
| Weighted Avg Shares Out | 32 | 20 | 11 | 8 |
| Weighted Avg Shares Out Dil | 32 | 20 | 11 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $0 |
| Interest Expense | $2 | $3 | $2 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$37 | -$27 | -$40 | -$33 |
| % Margin | – | – | – | – |